

2 3 4 **Vaccine Committee Meeting** July 31, 2025; 11:00 a.m. - 12:00 p.m. PT 5 I. Attendance. This meeting was conducted virtually. Participating in all or part of the meeting were the following individuals: Statutory Members 25 Libby Page, MPH, King County Public Health Ed Marcuse, MD, Emeritus Professor of Amy Person, MD, Benton-Franklin Health Pediatrics, University of Washington, Chair 10 27 John Dunn, MD, MPH, Kaiser 11 28 Kristi A. Rice, MD, Providence Jamilia Sherls, DNP, MPH, RN, CPN, CDP Sherri Zorn, MD, DOH & WVA Consultant 12 29 Hema Sivasubramanian, MD, Aetna 30 Julia Zell, MA, Esq., Executive Director 31 Administrative Staff 14 15 32 Cheri Cagle, Stakeholder Liaison Other Members Janel Jorgenson, WA DOH 16 33 Amy Carter, MD, Allegro Pediatrics Ashley Ithal, MPH, Project Support Leader 34 17 Carrie Jenner, MD, Pierce County 35 Patrick Miller, MPH, WVA, Administrative Immunization Coalition (PCIC) Director 19 36 Gretchen Lasalle, MD, Rockwood Clinic 37 Kerrie Walker, Deputy Manager Jennifer Maxwell, MD, Family Physician 38 21 Jay Miller, MD, Tacoma Pierce County Health 39 Other 40 Juliet Dang, CSL Seqirus 23 Department Gib Morrow, MD, Kitsap Public Health District 24 41 Bob Runnells, Informed Choice WA 42 43 II. Summary of Actions Taken and/or Recommended 44 45 Actions Taken (votes adopted) 46 i. To approve Vaccine Committee meeting minutes April 17, 2025. 47 III. 48 Minutes 49 50 Welcome and Introductions 51 At 11:02 a.m. Dr. Marcuse called the meeting to order and announced that the meeting would be recorded for the benefit of the minute taker. 52 53 54 Calendar Consent Items Dr. Marcuse asked for a motion to approve the minutes. Upon motion duly made and seconded, it was 55 56 unanimously 57 VOTED: To approve Vaccine Committee meeting minutes April 17, 2024. 58 IV. 59 Recent Events & WA Response 60 Measles/Pertussis 61 Dr. Marcuse provided an overview of measles and pertussis in WA and stated that the implications of 62 63 declaring an outbreak would be widespread. 64 ACIP, FDA, HHS Reorganization and WA Response, and VAC 65

Federal changes to the organizations responsible for vaccine approval and recommendations have added

confusion to vaccine distribution in WA and nationally. ACIP meetings are still occurring with a different

66

67

Meeting Minutes

Commented [PM1]: I would alphabetize them after Ed



panel of members recently appointed by the HHS Secretary. At its most recent meeting in June, ACIP decided to no longer support thimerosal containing vaccines. While this minimally impacts Washington, it is likely to impact other states. Dr. Dunn stated that CDC vaccine schedule changes would likely result in a myriad of issues related to vaccine uptake, outbreaks, etc.

Physician Perspective

 $\begin{array}{c} 100 \\ 101 \end{array}$

 Dr. Marcuse asked the physicians on the call to share their patient/parent experiences. Several observed a growing divide between those parents who worry about vaccine access while others resist vaccination altogether. Several reported that while parents have still been open to having conversations, those who felt hesitant about a vaccine schedule are reportedly more likely to either modify the schedule or not vaccinate at all.

V. Public Comments

Dr. Marcuse invited members of the public to speak if they had comments. Public comments were received from Mr. Runnells from Informed Choice Washington and Juliet Dang from Seqirus.

VI. Fall Ordering

Ms. Jorgenson provided an update on vaccines which will be available for respiratory season. She reported that influenza vaccines have already arrived at McKesson. She further highlighted that COVID-19 and RSV products were expected to be available in time for respiratory season. Ms. Jorgenson anticipated that vaccine distribution will be slow at the start of the respiratory season, which is typical. There will be a provider webinar, hosted by DOH, on August 21st related to 2025-26 respiratory season ordering controls.

VII. Limiting Vaccine Loss

Ms. Zell highlighted ongoing issues with provider billing and assessment collection and the associated impact on the current financial position of the WVA. She noted that the WVA is continuing to work with the DOH on Vaccine Assessment Loss (VAL) efforts including payer dosage-based assessment (DBA) compliance and provider outreach and education. Discussion took place regarding some of the drivers for VAL and strategies to address them.

VIII. Closing

The meeting adjourned at 12:00 p.m. PT.